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tatin Treatment
oes Not Cause Cancer*
aniel Steinberg, MD, PHD
a Jolla, California
n a previous issue of the Journal, Alsheikh-Ali et al. (1)
eported a meta-analysis of data from large-scale random-
zed clinical trials of statins. In that analysis, dealing only
ith the statin arms of the studies, they reported that the
ubjects with the lowest on-treatment levels of low-density
ipoprotein (LDL) cholesterol had a significantly higher risk
f developing cancer than those with higher on-treatment
DL levels. Needless to say, this report occasioned some
nease among patients taking statins and also among
hysicians (see comments by LaRosa [2], DeMaria and Ben
ehuda [3], and Kjekshus [4]). In this issue of the Journal,
he same authors now publish their analysis of data from
ubjects in the control arms of statin trials (5). They find
lmost exactly the same relationship, namely, that the
andomly recruited subjects who entered the studies with
ow LDL levels but were not treated with statins also had a
See pages 1141 and 1150
ignificantly higher cancer risk. Moreover, the slope of the
urve relating cancer risk to LDL level was almost identical
o that in the statin-treated group. In other words, as the
uthors point out, it turns out that the statins really had
othing to do with it. Untreated subjects with low LDL
evels on entry into the studies showed the same “low-LDL/
igher cancer risk” relationship. The authors now conclude
hat “. . . statin therapy, despite producing marked reduc-
ions in LDL-C, is not associated with an increased risk of
ancer” (5). This is, of course, in agreement with an
xtensive literature on the safety of statins, including the
onclusions of other meta-analyses (6,7). Here we have yet
nother example of an epidemiologic correlation mistakenly
nterpreted as possibly representing a causal connection. No,
tatin treatment does not cause cancer.
What accounts then for the apparent association between
ow LDL and cancer risk reported in the first article? Mostly
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.c
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alifornia.t reflects what Rose and Shipley (8) referred to over 30
ears ago as the “unsuspected sickness phenomenon” (i.e.,
he lowering of cholesterol levels by subclinical disease). We
now that cancers can significantly lower cholesterol levels
s much as 10 years before they surface clinically (9). The
andomly recruited cohorts in the large statin trials un-
oubtedly included some subjects who had low LDL levels
t the time they entered the study because they already had
ancer. It is well recognized that the curve describing the
elationship between initial LDL (or total cholesterol) and
ubsequent cancer incidence is J-shaped. In other words, if
ou measure serum cholesterol levels in a large, randomly
hosen population and then simply follow that population
or 5 years—without intervention of any kind—there will be
ore cancer deaths in those who had the lowest cholesterol
evels to begin with. Much of this (but perhaps not all) can
e attributed to the fact that subclinical cancer is lowering
he LDL levels in those subjects. This is especially true for
eukemias and other cancers of the hemopoietic system but
o some extent for all cancers. Tumor cells express high
evels of the LDL receptor and catabolize LDL at a higher
han normal rate (10). Thus, low LDL is the result, not the
ause, of the cancer. Subjects with latent cancers and very
ow initial LDL levels probably respond to statin therapy to
he same extent as the rest of the cohort. Consequently, they
ould still be in the statin-treated group with the lowest
DL levels. The excess cancer incidence in that low LDL
roup would then reflect their pre-existing disease, and the
ame would be true in both the statin-treated group and the
ontrol subjects. This is exactly what Alsheikh-Ali et al. (5)
ound. It is unfortunate that this analysis of the control
ohorts was not included in the first article.
It should be emphasized that what Alsheikh-Ali et al. (5)
bserved was that cancer risk correlated with the on-
reatment level of LDL. It did not correlate with the extent
f LDL reduction induced by the statins, whether expressed
n relative terms (percentage fall) or in absolute terms (fall in
g/dl). Incidentally, the title of the first report was mis-
eading in this respect: “Effect of the Magnitude of Lipid
owering [emphasis added] on Risk of . . . Cancer.” They
ere observing not an effect of statin treatment, but the
unsuspected sickness phenomenon” with the distribution
urve for LDL shifted to the left by statin treatment.
While pre-existing cancer can account for most of the
-shaped curve, it may not account for all of it. When
ancers surfacing during the first few years are excluded
rom consideration, on the assumption that those cancers
ust have been already present at the time the study began,
he LDL/cancer relationship weakens considerably but does
ot reach zero. Even after eliminating all cancers that
urface during the first 5 years, there is a small residual
xcess in the low LDL group (11). However, there is
vidence that low initial LDL values can be observed for as
ong as 10 years before the cancer surfaces (9). Also, other
hronic diseases, such as alcoholism or cirrhosis, can lower
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September 30, 2008:1148–9 Editorial Commentholesterol levels and also predispose to cancer, possibly
ccounting for the sometimes long gap between the initial
owering of LDL and the ultimate expression of the cancer.
The central question for the clinician is whether a low
DL carries with it any intrinsic danger of cancer or other
erious consequences (leaving aside for the moment possible
ide effects of the therapeutic intervention). Almost cer-
ainly not. Most mammals have LDL levels around 40 to 50
g/dl all their lives (12). Our cord blood LDL levels are in
hat range. Some patients with hypobetalipoproteinemia do
ery nicely (even demonstrate longevity) with LDL levels as
ow as 10 to 20 mg/dl (13). Cellular levels of cholesterol are
ealously guarded by the LDL receptor pathway of Brown
nd Goldstein (14), and the LDL receptor in peripheral
issues is still 50% saturated at a plasma LDL of only 10
g/dl. Thus, the cells continue to take up as much LDL as
hey need even when LDL levels are extremely low. There
hould be no hesitation in aiming for LDL levels of 50 to 70
g/dl in high-risk patients. Indeed a strong case can be
ade for even earlier and more aggressive treatment of
ypercholesterolemia (15).
Neither statin treatment itself nor the low LDL levels
nduced by statins increases the risk of cancer.
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